Correlation Between GlaxoSmithKline PLC and RBC Canadian

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both GlaxoSmithKline PLC and RBC Canadian at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining GlaxoSmithKline PLC and RBC Canadian into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between GlaxoSmithKline PLC ADR and RBC Canadian Equity, you can compare the effects of market volatilities on GlaxoSmithKline PLC and RBC Canadian and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in GlaxoSmithKline PLC with a short position of RBC Canadian. Check out your portfolio center. Please also check ongoing floating volatility patterns of GlaxoSmithKline PLC and RBC Canadian.

Diversification Opportunities for GlaxoSmithKline PLC and RBC Canadian

-0.93
  Correlation Coefficient

Pay attention - limited upside

The 3 months correlation between GlaxoSmithKline and RBC is -0.93. Overlapping area represents the amount of risk that can be diversified away by holding GlaxoSmithKline PLC ADR and RBC Canadian Equity in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on RBC Canadian Equity and GlaxoSmithKline PLC is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on GlaxoSmithKline PLC ADR are associated (or correlated) with RBC Canadian. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of RBC Canadian Equity has no effect on the direction of GlaxoSmithKline PLC i.e., GlaxoSmithKline PLC and RBC Canadian go up and down completely randomly.

Pair Corralation between GlaxoSmithKline PLC and RBC Canadian

Considering the 90-day investment horizon GlaxoSmithKline PLC ADR is expected to under-perform the RBC Canadian. In addition to that, GlaxoSmithKline PLC is 2.43 times more volatile than RBC Canadian Equity. It trades about -0.3 of its total potential returns per unit of risk. RBC Canadian Equity is currently generating about 0.25 per unit of volatility. If you would invest  3,081  in RBC Canadian Equity on August 29, 2024 and sell it today you would earn a total of  95.00  from holding RBC Canadian Equity or generate 3.08% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthSignificant
Accuracy95.65%
ValuesDaily Returns

GlaxoSmithKline PLC ADR  vs.  RBC Canadian Equity

 Performance 
       Timeline  
GlaxoSmithKline PLC ADR 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days GlaxoSmithKline PLC ADR has generated negative risk-adjusted returns adding no value to investors with long positions. Despite uncertain performance in the last few months, the Stock's basic indicators remain quite persistent which may send shares a bit higher in December 2024. The latest mess may also be a sign of long-standing up-swing for the company institutional investors.
RBC Canadian Equity 

Risk-Adjusted Performance

20 of 100

 
Weak
 
Strong
Solid
Compared to the overall equity markets, risk-adjusted returns on investments in RBC Canadian Equity are ranked lower than 20 (%) of all funds and portfolios of funds over the last 90 days. Despite somewhat weak basic indicators, RBC Canadian may actually be approaching a critical reversion point that can send shares even higher in December 2024.

GlaxoSmithKline PLC and RBC Canadian Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with GlaxoSmithKline PLC and RBC Canadian

The main advantage of trading using opposite GlaxoSmithKline PLC and RBC Canadian positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if GlaxoSmithKline PLC position performs unexpectedly, RBC Canadian can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in RBC Canadian will offset losses from the drop in RBC Canadian's long position.
The idea behind GlaxoSmithKline PLC ADR and RBC Canadian Equity pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.

Other Complementary Tools

Fundamental Analysis
View fundamental data based on most recent published financial statements
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges